These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 27090178)

  • 1. Impact of Fluoroquinolone Exposure Prior to Tuberculosis Diagnosis on Clinical Outcomes in Immunocompromised Patients.
    Lee JY; Lee HJ; Kim YK; Yu S; Jung J; Chong YP; Lee SO; Choi SH; Shim TS; Kim YS; Woo JH; Kim SH
    Antimicrob Agents Chemother; 2016 Jul; 60(7):4005-12. PubMed ID: 27090178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence, treatment, and outcomes of isoniazid mono-resistant Mycobacterium tuberculosis infections in Alberta, Canada from 2007-2017.
    Edwards BD; Edwards J; Cooper R; Kunimoto D; Somayaji R; Fisher D
    PLoS One; 2020; 15(3):e0229691. PubMed ID: 32155169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Empirical use of fluoroquinolones improves the survival of critically ill patients with tuberculosis mimicking severe pneumonia.
    Tseng YT; Chuang YC; Shu CC; Hung CC; Hsu CF; Wang JY
    Crit Care; 2012 Oct; 16(5):R207. PubMed ID: 23098258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved survival in patients with severe tuberculosis after exposure to fluoroquinolones.
    Chiang SR; Shieh JM; Chen CH; Hsing SC; Wen SF; Wang JJ; Cheng KC; Chuang YC
    Infect Dis (Lond); 2016; 48(11-12):789-95. PubMed ID: 27329552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluoroquinolone exposure prior to tuberculosis diagnosis is associated with an increased risk of death.
    van der Heijden YF; Maruri F; Blackman A; Holt E; Warkentin JV; Shepherd BE; Sterling TR
    Int J Tuberc Lung Dis; 2012 Sep; 16(9):1162-7. PubMed ID: 22794509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical impact of using fluoroquinolone with low antimycobacterial activity on treatment delay in tuberculosis: Hospital-based and population-based cohort study.
    Lee MR; Lee CH; Wang JY; Lee SW; Ko JC; Lee LN
    J Formos Med Assoc; 2020 Jan; 119(1 Pt 2):367-376. PubMed ID: 31262613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas.
    Wang JY; Hsueh PR; Jan IS; Lee LN; Liaw YS; Yang PC; Luh KT
    Thorax; 2006 Oct; 61(10):903-8. PubMed ID: 16809417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Study on the efficacy and safety of short-term treatment including fluoroquinolones anti-tuberculosis drugs for rifampicin resistant pulmonary tuberculosis].
    Kang WL; Xie YG; Tan WG; Chu NH; Li L; You YH; Yang YZ; Wang XM; Yan XL; Miao ZP; Duanmu HJ
    Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Feb; 30(2):179-83. PubMed ID: 19565883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of pulmonary MDR-TB: impacts of fluoroquinolone resistance and linezolid treatment.
    Jeong BH; Jeon K; Park HY; Kwon OJ; Lee KS; Kim HK; Choi YS; Kim J; Huh HJ; Lee NY; Koh WJ
    J Antimicrob Chemother; 2015 Nov; 70(11):3127-33. PubMed ID: 26203184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluoroquinolone resistance in renal isolates of Mycobacterium tuberculosis.
    Webster D; Long R; Shandro C; Pettipas J; Leblanc J; Davidson R; Fanning A
    Int J Tuberc Lung Dis; 2010 Feb; 14(2):217-22. PubMed ID: 20074414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of fluoroquinolone use in patients with hepatotoxicity induced by anti-tuberculosis regimens.
    Ho CC; Chen YC; Hu FC; Yu CJ; Yang PC; Luh KT
    Clin Infect Dis; 2009 Jun; 48(11):1526-33. PubMed ID: 19400686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is the delay in diagnosis of pulmonary tuberculosis related to exposure to fluoroquinolones or any antibiotic?
    Wang M; Fitzgerald JM; Richardson K; Marra CA; Cook VJ; Hajek J; Elwood RK; Bowie WR; Marra F
    Int J Tuberc Lung Dis; 2011 Aug; 15(8):1062-8. PubMed ID: 21740669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluoroquinolone-resistant Pseudomonas aeruginosa: risk factors for acquisition and impact on outcomes.
    Hsu DI; Okamoto MP; Murthy R; Wong-Beringer A
    J Antimicrob Chemother; 2005 Apr; 55(4):535-41. PubMed ID: 15728150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of fluoroquinolone antibiotics leads to tuberculosis treatment delay in a South African gold mining community.
    Jeon CY; Calver AD; Victor TC; Warren RM; Shin SS; Murray MB
    Int J Tuberc Lung Dis; 2011 Jan; 15(1):77-83. PubMed ID: 21276301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment outcomes and survival based on drug resistance patterns in multidrug-resistant tuberculosis.
    Kim DH; Kim HJ; Park SK; Kong SJ; Kim YS; Kim TH; Kim EK; Lee KM; Lee SS; Park JS; Koh WJ; Lee CH; Shim TS
    Am J Respir Crit Care Med; 2010 Jul; 182(1):113-9. PubMed ID: 20224066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors associated with fluoroquinolone-resistant tuberculosis in a Beijing tuberculosis referral hospital.
    Liu CH; Yang N; Wang Q; Hu YL; Li L; Zhang GY; Zhu B
    Respirology; 2011 Aug; 16(6):918-25. PubMed ID: 21564401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of fluoroquinolones for the treatment of TB: 8 years of experience.
    Ferrand H; Blanc-Gruyelle AL; Amsilli M; Lemaire X; Papot E; Papy E; Bervar J; Senneville E; Bouvet E; Yazdanpanah Y
    J Antimicrob Chemother; 2015 Nov; 70(11):3166-7. PubMed ID: 26260132
    [No Abstract]   [Full Text] [Related]  

  • 18. Moxifloxacin plus standard first-line therapy in the treatment of pulmonary tuberculosis: A meta-analysis.
    Chen Z; Liang JQ; Wang JH; Feng SS; Zhang GY
    Tuberculosis (Edinb); 2015 Jul; 95(4):490-6. PubMed ID: 25964137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Benefit of Appropriate Empirical Fluoroquinolone Therapy for Adults with Community-Onset Bacteremia in Comparison with Third-Generation-Cephalosporin Therapy.
    Lee CC; Wang JL; Lee CH; Hsieh CC; Hung YP; Hong MY; Tang HJ; Ko WC
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27855072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical features and outcomes of tuberculosis in solid organ transplant recipients.
    Bodro M; Sabé N; Santín M; Cruzado JM; Lladó L; González-Costello J; Carratalà J
    Transplant Proc; 2012 Nov; 44(9):2686-9. PubMed ID: 23146494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.